Tokyo Tape
Sign in
← M3

Quarterly report · Q3

2413.TEDINET S100SS2U
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥179.2bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥63.4bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥55.0bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥20.4bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥57.3bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥20.0bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥36.6bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥13.2bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥38.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥13.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥463.8bnat 2023-12-31Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥380.7bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥112.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥351.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥337.1bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥143.1bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥35.6bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.3bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥13.9bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.932023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.452023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.892023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.442023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio72.7%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥459m
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥584m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥31m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥3.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥549m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥20.3bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥6.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥248m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥32m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥1.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-12-31¥71.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-10-01 → 2023-12-31¥26.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-12-31¥69.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-10-01 → 2023-12-31¥25.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥2.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥710m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-12-31¥30.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-10-01 → 2023-12-31¥11.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥15m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥4m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-12-31¥12.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-10-01 → 2023-12-31¥5.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥3m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥2.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥842m
—segment totalrevenue2023-04-01 → 2023-12-31¥179.8bn
—segment totalrevenue2023-10-01 → 2023-12-31¥63.4bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥177.3bn
—segment totalrevenue external2023-10-01 → 2023-12-31¥62.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥2.5bn
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥759m
—segment totalsegment profit2023-04-01 → 2023-12-31¥54.9bn
—segment totalsegment profit2023-10-01 → 2023-12-31¥20.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 773
ItemContextValueUnit
Intersegment revenue IFRSCurrentQuarterDuration－JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember25977000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember6478000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember3496000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember8021000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember19468000000JPY
Revenue IFRSCurrentQuarterDuration_ReportableSegmentsMember63440000000JPY
Revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember733000000JPY
Revenue IFRSCurrentQuarterDuration_ReconcilingItemsMember-779000000JPY
Revenue IFRSCurrentQuarterDuration63394000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember11944000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember1541000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember549000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember842000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember5595000000JPY
Operating profit loss IFRSCurrentQuarterDuration_ReportableSegmentsMember20471000000JPY
Operating profit loss IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember517000000JPY
Operating profit loss IFRSCurrentQuarterDuration_ReconcilingItemsMember-584000000JPY
Operating profit loss IFRSCurrentQuarterDuration20404000000JPY
Finance income and expenses net IFRSCurrentQuarterDuration-401000000JPY
Profit loss before tax IFRSCurrentQuarterDuration20003000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember712000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember140000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember48000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember428000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember899000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_ReportableSegmentsMember2227000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember40000000JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration_ReconcilingItemsMember－JPY
Depreciation and amortization operating expenses IFRSCurrentQuarterDuration2267000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-09
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第24期第３四半期（自　2023年10月１日　至　2023年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)エムスリー株式会社
Company name in english cover pageFilingDateInstantM3, Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　谷　村　　　格
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区赤坂一丁目11番44号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03（6229）8900（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員　　　　　大　場　　　啓　史
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区赤坂一丁目11番44号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03（6229）8900（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員　　　　　大　場　　　啓　史
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05425
Fund codeFilingDateInstant－
Security codeFilingDateInstant24130
Filer name in japaneseFilingDateInstant
Original text (Japanese)エムスリー株式会社
Filer name in englishFilingDateInstantM3, Inc.

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass